Evolus, Inc. (EOLS) Stock Analysis & Investment Frameworks
Evolus, Inc. (EOLS) stock analysis on Invetso. Review Evolus, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Evolus, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Evolus, Inc. Key Financial Metrics
- Market Cap: $463.01M
- Revenue: $297.18M
- ROE: 123.11%
- ROIC: -15.27%
- Dividend Yield: N/A
About Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Evolus, Inc. Investment Frameworks
Invetso analyzes Evolus, Inc. (EOLS) across the following frameworks:
- Evolus, Inc. 10Y Growth Potential
- Evolus, Inc. Scenario Analysis
- Evolus, Inc. Risks & Opportunities
- Evolus, Inc. Economic Moat
- Evolus, Inc. Business Model
- Evolus, Inc. Management
- Evolus, Inc. SWOT Analysis
- Evolus, Inc. Porter's 5 Forces
- Evolus, Inc. PESTLE Analysis
- Evolus, Inc. ESG Analysis